Skip to main content
KalVista Pharmaceuticals, Inc logo
Menu toggle

Main navigation

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • KalVista for DME
  • For Patients
    • HAE Resources
    • DME Resources
  • For Healthcare Providers
    • HAE Resources
    • DME Resources
    • Publications
  • For Investors
    • Stock Information
    • News Releases
    • Events Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

KalVista Pharmaceuticals
creating a new generation of small molecule protease inhibitors for HAE and DME

Hereditary Angioedema (HAE)

Diabetic Macular Edema (DME)

News

Kalvista Pharmaceuticals

KalVista Pharmaceuticals Appoints Brian J. G. Pereira, MD to Board of Directors

Feb 1, 2019
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans

Jan 4, 2019
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

Dec 14, 2018
All News

Footer

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2019 | All rights reserved.

Footer Bottom

  • KalVista Terms
  • Privacy
`